Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 7/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.73 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.73 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.73 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.73 |
| ▸ | STAT3 | P40763 | 2/20 | 0.69 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.60 |
| ▸ | GSK3B | P49841 | 2/20 | 0.57 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24376929 | 1.00 | CRBN (0.73) | CRBNHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL27267629 | 1.00 | CRBN (0.73) | CRBNHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL29622144 | 1.00 | CRBN (0.73) | CRBNHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL24558580 | 1.00 | CRBN (0.73) | CRBNHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL22326312 | 1.00 | CRBN (0.73) | CRBNHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL24765180 | 1.00 | CRBN (0.73) | CRBNHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL23702529 | 0.99 | CRBN (0.74) | CRBNHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL23636449 | 0.97 | CRBN (0.75) | CRBNHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL26320196 | 0.94 | STAT3 (0.76) | CRBNHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL25036554 | 0.94 | CRBN (0.69) | CRBNHDAC1HDAC6HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522158-A2 | PAK1 DEGRADERS AND METHODS OF USE THEREOF | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220722-A2 | PAK1 DEGRADERS AND METHODS OF USE THEREOF | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2022086937-A9 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022086937-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-04-28 | — | — | WO | disclosed |